Navigation Links
Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
Date:9/17/2007

Rapid, highly sensitive diagnostic provides patient HIV tropism status needed to initiate therapy with Pfizer's recently approved Selzentry(TM)

(Maraviroc), CCR5 antagonist.

MALIBU, Calif., Sept. 17 /PRNewswire/ -- Pathway Diagnostics announces nationwide availability of SensiTrop(TM), its proprietary molecular heteroduplex tracking assay (HTA) for determining the co-receptor tropism status of HIV infected patients. Pathway performs the SensiTrop(TM) assay in its CLIA approved laboratory on samples received from Mayo Medical Laboratories and other soon-to-be named national laboratories.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070917/LAM073LOGO)

Recently Pfizer Inc. and the FDA announced the approval of Selzentry(TM) (Maraviroc), the first in a novel class of anti-retroviral drugs based on blocking the CCR5 co-receptor of HIV. Selzentry, in combination with other antiretroviral agents, is indicated for treatment-experienced adult HIV patients with only CCR5-tropic HIV-1 detectable who have evidence of viral replication, and HIV-1 strains resistant to multiple anti-retroviral agents. The FDA label states that when initiating therapy, tropism testing and treatment history should guide the use of Selzentry.

"Pathway is pleased to introduce this second generation diagnostic HIV tropism assay nationwide, providing clinicians a fast, sensitive and economical testing alternative to the currently available biological HIV tropism assay," said Walter Narajowski, Pathway Diagnostics President and CEO. "This timely introduction of SensiTrop is a perfect example of Pathway's strategy to license proprietary biomarkers, develop them, and rapidly commercialize them with diagnostic partners."

SensiTrop(TM) is a molecular based assay designed and demonstrated to be highly-sensitive in detecting CXCR4-tropic HIV in patient samples that contain as little as 1% CXCR4. "The combination of SensiTrop's high-sensitivity and rapid turn-around-time (less than 7 days) will be extremely valuable to HIV physicians and patients when utilizing co-receptor tropism status to guide the use of Selzentry," said Terry Robins Ph.D., Vice President of Research and Development at Pathway Diagnostics.

About HIV Co-receptor tropism and the SensiTrop(TM) assay

The ability of the HIV virus to infect different cell types utilizing different cell surface receptors is referred to as HIV co-receptor tropism. One type of HIV that utilizes the CCR5 co-receptor has been shown to be blocked by CCR5 antagonist drugs such as Selzentry. A different type of HIV that utilizes the CXCR4 co-receptor is not blocked by CCR5 antagonists. Therefore, determining the tropism status of HIV-infected patients has been indicated by the FDA before initiating CCR5 antagonist therapy.

Pathway's SensiTrop(TM) assay is a molecular hybridization technique based on heteroduplex tracking technology developed by Dr. Barbara Weiser and Dr. Harold Burger's laboratory at the Wadsworth Center, New York State Department of Health, Albany NY. Heteroduplex tracking technology interrogates the complete HIV V3 loop, detecting sequence differences that determine whether the patient's HIV utilizes either the CXCR4 or CCR5 co-receptor. SensiTrop, like other molecular based assays, is highly sensitive and rapid to perform.

About Pathway Diagnostics

Pathway Diagnostics Corporation focuses on the development, validation and commercialization of novel, proprietary biomarker assays across multiple disease areas that address unmet medical needs and improve patient care. The company combines assay development expertise with a broad range of advanced technology platforms, a fully licensed CLIA laboratory, and a growing portfolio of patent-protected biomarkers for pharmaceutical companies to use in drug development and for commercial reference laboratories and in vitro diagnostic manufacturers to license for use in patient testing. Pathway effectively bridges the gap between biomarker research and biomarker commercialization, as well as ensures a regulatory-compliant environment for laboratory testing for preclinical and clinical drug development programs.

http:/www.Pathwaydx.com


'/>"/>
SOURCE Pathway Diagnostics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
2. Scientists Identify Cancer Pathway
3. Citrinin, a fungal toxin, induces apoptosis via mitochondrial pathway
4. Tooth Decay Bacteria Unaffected By Altered Biochemical Pathway
5. Mice model to study bacterial therapeutic pathway
6. Unchecked Cellular Repair Pathway Causes Liver Cancer
7. Lack of Funds in Sudan-Pathway to Epidemic Outbreaks
8. Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss
9. Birth Defects Caused By Deficiencies In Cell Signaling Pathway
10. Discovery of A New Genetic Pathway Could Lead To Treatment Of Skin Problems And Cancer
11. Cellular Pathway Yields Potential New Weapon in Vaccine Arsenal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing list ... seven other locations throughout the Southeast, from Orlando to Huntsville and in between. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are ... patients. Research shows that the Goal Attainment Scale (GAS) captures 20% more change ... and learn more about the Goal Attainment Scale, Education Resources Inc. is offering ...
(Date:2/10/2016)... ... 10, 2016 , ... IDEX Health & Science, LLC announces ... (PLS) columns combine the strength of traditional stainless steel with the chemical inertness ... while operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow ...
(Date:2/10/2016)... ... 10, 2016 , ... Anxiety of older Americans over steep cost increases of ... a decade ago, according to The Senior Citizens League (TSCL). Since ... coping with rapidly rising costs. “The implications are chilling, particularly for people with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk Solutions, ... today announced the launch of LexisNexis Provider ... that helps improve and optimize the quality and ... performance using severity-adjusted scores. By measuring provider performance ... solution to deliver better outcomes, improve the patient ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: